File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Remifentanil reduces the release of biochemical markers of myocardial damage in patients undergoing on pump coronary artery bypass surgery

TitleRemifentanil reduces the release of biochemical markers of myocardial damage in patients undergoing on pump coronary artery bypass surgery
Authors
KeywordsMyocardial protection
Opioid
Remifentanil
Cardiac surgery
Issue Date2009
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/jvca
Citation
The 2009 Annual Scientific Meeting of the Australian and New Zealand College of Anaesthetists (ANZCA), Cairns, QLD., Australia, 2-6 May 2009. How to Cite?
AbstractINTERVENTIONS: Patients randomized to the remifentanil group (n = 20) received a 1 µg/kg bolus followed by 0.5 µg/kg/min infusion for 30 minutes after induction but before sternotomy, whilst the control group (n = 20) received normal saline. Serial samples for measurement of creatine kinase (CKMB), cardiac troponin I (cTnI), ischemia modified albumin (IMA) and heart type fatty acid binding protein (hFABP) were taken at baseline, pre bypass, T = 10 minutes, 2, 6, 12, and 24 hours after cross clamp release, to assess the degree of myocardial damage. MEASUREMENTS AND MAIN RESULTS: Patients in the remifentanil group had lower levels of CKMB from T _ 2 hours to 24 hours, cTnI from T = 10 minutes to T = 12 hours, IMA from T = 10 min to T = 2 hours and h-FABP from T _ 10 minutes to T = 12 hours (p < 0.05). The time to tracheal extubation was shorter in patients in the remifentanil group. The overall length of ICU and hospital stays was not different. CONCLUSIONS: The addition of remifentanil to the anesthesia regimen reduced the degree of myocardial damage. This incremental benefit may be attributable to either to remifentanil itself or to an overall increased opioid dose, the latter may be necessary to trigger cardiac protection. © 2009 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/63439
ISSN
2015 Impact Factor: 1.519
2015 SCImago Journal Rankings: 0.646

 

DC FieldValueLanguage
dc.contributor.authorWong, GTC-
dc.contributor.authorHuang, Z-
dc.contributor.authorIrwin, MG-
dc.date.accessioned2010-07-13T04:23:39Z-
dc.date.available2010-07-13T04:23:39Z-
dc.date.issued2009-
dc.identifier.citationThe 2009 Annual Scientific Meeting of the Australian and New Zealand College of Anaesthetists (ANZCA), Cairns, QLD., Australia, 2-6 May 2009.-
dc.identifier.issn1053-0770-
dc.identifier.urihttp://hdl.handle.net/10722/63439-
dc.description.abstractINTERVENTIONS: Patients randomized to the remifentanil group (n = 20) received a 1 µg/kg bolus followed by 0.5 µg/kg/min infusion for 30 minutes after induction but before sternotomy, whilst the control group (n = 20) received normal saline. Serial samples for measurement of creatine kinase (CKMB), cardiac troponin I (cTnI), ischemia modified albumin (IMA) and heart type fatty acid binding protein (hFABP) were taken at baseline, pre bypass, T = 10 minutes, 2, 6, 12, and 24 hours after cross clamp release, to assess the degree of myocardial damage. MEASUREMENTS AND MAIN RESULTS: Patients in the remifentanil group had lower levels of CKMB from T _ 2 hours to 24 hours, cTnI from T = 10 minutes to T = 12 hours, IMA from T = 10 min to T = 2 hours and h-FABP from T _ 10 minutes to T = 12 hours (p < 0.05). The time to tracheal extubation was shorter in patients in the remifentanil group. The overall length of ICU and hospital stays was not different. CONCLUSIONS: The addition of remifentanil to the anesthesia regimen reduced the degree of myocardial damage. This incremental benefit may be attributable to either to remifentanil itself or to an overall increased opioid dose, the latter may be necessary to trigger cardiac protection. © 2009 Elsevier Inc. All rights reserved.-
dc.languageeng-
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/jvca-
dc.relation.ispartofJournal of Cardiothoracic and Vascular Anesthesia-
dc.rights© 2009. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectMyocardial protection-
dc.subjectOpioid-
dc.subjectRemifentanil-
dc.subjectCardiac surgery-
dc.titleRemifentanil reduces the release of biochemical markers of myocardial damage in patients undergoing on pump coronary artery bypass surgery-
dc.typeConference_Paper-
dc.identifier.emailWong, GTC: gordontcwong@hotmail.com-
dc.identifier.emailHuang, Z: zyhuang@HKUCC.hku.hk-
dc.identifier.emailIrwin, MG: mgirwin@hkucc.hku.hk-
dc.identifier.authorityWong, GTC=rp00523-
dc.identifier.authorityIrwin, MG=rp00390-
dc.description.naturepostprint-
dc.identifier.hkuros161743-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats